Sabine Zitzmann-Kolbe

Simultaneous Inhibition of PI3Kδ and PI3Kα Induces ABC-DLBCL Regression by Blocking BCR-Dependent and -Independent Activation of NF-κB and AKT

Juliane Paul, Maurice Soujon, Antje M. Wengner et al. · Cancer Cell · 2017 · 145 citations

Life Sciences, Cancer Biology, Molecular Biology +15

Preclinical Efficacy of a PSMA-Targeted Thorium-227 Conjugate (PSMA-TTC), a Targeted Alpha Therapy for Prostate Cancer

Stefanie Hammer, Urs B. Hagemann, Sabine Zitzmann-Kolbe et al. · Clinical Cancer Research · 2019 · 121 citations · Full text

Medicine, Oncology, Pharmacology +17

Inhibition of BUB1 Kinase by BAY 1816032 Sensitizes Tumor Cells toward Taxanes, ATR, and PARP Inhibitors <i>In Vitro</i> and <i>In Vivo</i>

Gerhard Siemeister, Anne Mengel, Amaury E. Fernández‐Montalván et al. · Clinical Cancer Research · 2018 · 79 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +17

Anetumab ravtansine inhibits tumor growth and shows additive effect in combination with targeted agents and chemotherapy in mesothelin-expressing human ovarian cancer models

Maria Quanz, Urs B. Hagemann, Sabine Zitzmann-Kolbe et al. · Oncotarget · 2018 · 60 citations · Full text

Medicine, Oncology, Pharmacology +17

Immunostimulatory effects of targeted thorium-227 conjugates as single agent and in combination with anti-PD-L1 therapy

Pascale Lejeune, Véronique Cruciani, Axel Berg‐Larsen et al. · Journal for ImmunoTherapy of Cancer · 2021 · 52 citations · Full text

Life Sciences, Immunology, Oncology +17